Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) The role of FDG PET-CT in differential diagnosis of pleural pathologies
Journal Information
Vol. 31. Issue 4.
Pages 187-191 (July - August 2012)
Share
Share
Download PDF
More article options
Visits
1085
Vol. 31. Issue 4.
Pages 187-191 (July - August 2012)
Original article
The role of FDG PET-CT in differential diagnosis of pleural pathologies
El papel de FDG PET-TAC en el diagnóstico diferencial de patologías pleurales
Visits
1085
U. Elbogaa,
Corresponding author
umutelboga@hotmail.com

Corresponding author.
, M. Yılmaza, M. Uyarb, Y. Zeki Çelena, K. Bakırc, Ö. Dikensoyb
a Department of Nuclear Medicine, University of Gaziantep, School of Medicine, Gaziantep, Turkey
b Department of Pulmonary Medicine, University of Gaziantep, School of Medicine, Gaziantep, Turkey
c Department of Pathology, University of Gaziantep, School of Medicine, Gaziantep, Turkey
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (3)
Table 1. Patients’ data and FDG PET-CT results in histopathologically malignant pleural mesothelioma group with subtypes.
Table 2. Patients’ data and FDG PET-CT results in histopathologically benign group.
Table 3. Summary of FDG PET-CT results according to histopathological diagnosis.
Show moreShow less
Abstract
Objective

This study has aimed to evaluate the impact of F18 Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG PET-CT) in the differential diagnosis of malignant and benign pleural lesions in patients with suspected malignant pleural mesothelioma (MPM).

Material and methods

Fifty patients (32 females, 18 males; age range 24–79 years) with pleural thickening, fluid, plaques or calcification on previous CT scan were examined with FDG PET-CT. PET-CT imaging was obtained 1h after FDG injection. In 12 patients, delayed imaging from the thoracic region was performed 2h after injection. FDG uptake was evaluated visually and semiquantitively using standardized uptake value (SUV). FDG PET-CT findings were compared with histopathologic diagnosis.

Results

Thirty-nine patients had increased FDG uptake in pleural lesions but PET-CT results were negative in 11 patients. When compared with histopathological results in FDG positive group, 34 patients had MPM, 5 had benign pathology; in FDG negative group 8 patients had benign pathology, 3 had MPM. Of patients with delayed imaging, 9 showed increased SUV but 3 had a decreased SUV on delayed images. Increased SUV group had 4 MPM, 5 benign pathology (3 chronic granulomatous inflammation, 2 benign asbestotic plaque). Decreased SUV group all had benign pathology (fibrosis, chronic inflammation, myofibrosis).

Discussion

FDG PET-CT is a useful imaging modality in differential diagnosis of malignant and benign pleural lesions. Delayed imaging seems to be useful if there is a decrease in SUV suggesting a benign pathology but does not seem to contribute to the differential diagnosis if the SUV is increased.

Keywords:
FDG PET-CT
Pleural thickening
Malignant pleural mesothelioma
Resumen
Introduccıón

El propósito de este estudio fue el de estudiar el impacto de F-18 Fluoro Desoxi Tomografía-Tomografía por Emisión de tomografía computerizada (FDG y PET-TAC) sobre la diagnosis diferencial de lesiones benignas y malignas en pacientes con sospecha de mesotelioma pleural maligno.

Pacientes y métodos

Cincuenta pacientes (32 mujeres, 18 hombres, rango de edad 24-79 años, edad media 57,6) con engrosamiento pleural, derrame pleural, placas o calcificaciones vistas en imágenes en estudios previos con TAC fueron sometidos a la PET-TAC con FDG. Tras la inyección intravenosa de la FDG, se realizaron imágenes PET-TAC al cabo de una hora. Se obtuvieron imágenes tardías de la región torácica a las 2 horas de la inyección. Se llevaron a cabo análisis visual y semi cuantitativos con el valor de captación estándar (SUV). Los resultados del FDG PET-TAC fueron comparados con el diagnóstico histopatológico.

Resultados

39 pacientes demostraron captación aumentada en lesiones pleurales. Los resultados en la PET-TAC fueron negativos en 11 pacientes. Al comparar los resultados histopatológicos en el grupo de FDG-positivo, 34 pacientes tenían mesotelioma pleural maligno (MPM), 5 pacientes tenían patologías benignas. En el grupo FDG-negativo, las patologías fueron benignas en 8 pacientes, 3 pacientes tuvieron MPM. En los pacientes con imágenes tardías, 9 demostraron SUV aumentado, pero 3 tuvieron SUV disminuido en las imágenes tardías. En el grupo con SUV aumentado, 4 tuvieron MPM, 5 patología benigna (3, inflamación granulomatosa, y 2 placas asbestosis benignos). En el grupo de SUV disminuido, todos tuvieron patología benigna (la fibrosis, inflamación crónica, miofibrosis).

Dıscusıón

La FDG PET-TAC es una modalidad de imágenes útil en el diagnóstico diferencial de lesiones pleurales benignas y malignas. Imágenes tardías parecen ser útiles si existe una disminución en SUV sugerente de una patología benigna. Sin embargo, no parece contribuir a un diagnóstico diferencial si el SUV se aumenta.

Palabras clave:
FDG PET/TAC
Engrosamiento pleural
Mesotelioma pleural maligno

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.remnie.2022.09.005
No mostrar más